Vertex Pharmaceuticals is trading 5.96% down now at $484.83 after no new company-specific announcement was identified for August 17, 2026; the catalyst remains unconfirmed.

  • Latest major developments were its August 3 earnings release and regulatory clearances for the approximately $10 billion Crinetics acquisition; both predated this move.
  • The S&P 500 was also down 0.50%, but that does not clearly explain the substantially larger after-hours decline.